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Abstract
Background: The use of genotyping to distinguish recrudescent from new infections is currently
recommended for all clinical antimalarial efficacy trials by the World Health Organization.
However, genotyping-adjusted drug efficacy estimates may vary between trials due to the use of
different genotyping methods and to the different settings in which these methods are applied.
Methods: A systematic review of all clinical antimalarial efficacy trials published from 1995–2005
was performed to characterize the use of genotyping, including the methods used and the effect of
these methods on estimates of drug efficacy.
Results: In a multivariate analysis, the method of interpretation of genotyping results, the studied
therapy, the location of the trial, and the duration of study follow-up all had statistically significant
effects on the percent of genotyped outcomes classified as new infections.
Conclusion:  Criteria for defining appropriate, standardized genotyping methods for use in
different settings are needed to enable more accurate estimates of antimalarial drug efficacy and
better comparison between trials. The advantages and disadvantages of different genotyping
methods and their potential impact in various settings are discussed.
Background
The spread of antimalarial drug resistance in Plasmodium
falciparum has led to serious setbacks in global malaria
control and stimulated an urgent search for new treat-
ments[1]. Monitoring of antimalarial drug efficacy and
policy decision making is generally based on the results of
clinical antimalarial trials. To adequately assess response
to antimalarial therapy in clinical trials, the World Health
Organization (WHO) currently recommends that patients
be followed for a minimum of 28 days, as treatment fail-
ures may occur a number of weeks after therapy[2]. Anti-
malarial efficacy trials usually occur in areas where
malaria is endemic and, therefore, patients may be treated
successfully but newly infected with parasites during the
follow-up period. When subjects have recurrent parasitae-
mia following therapy, it is not possible to clinically dis-
tinguish between a recrudescence due to drug failure and
a new infection. To make this distinction, molecular gen-
otyping techniques have been used to determine whether
recurrent parasitaemia is due to the same parasite
strain(s), indicating recrudescence, or different strain(s),
indicating new infection.
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The use of genotyping in antimalarial trials has become
more important in recent years due to longer follow-up
periods and the use of more efficacious drugs such as
artemisinin combination therapies (ACTs), as both of
these factors increase the proportion of subjects with
recurrent parasitaemia who have new infections. The
WHO now recommends genotyping be used for all anti-
malarial efficacy trials if available[3]. However, genotyp-
ing techniques have not been standardized, results may
vary between laboratories[4], and different methods of
interpretation may have a large effect on estimates of treat-
ment efficacy[5]. To characterize changing patterns of gen-
otyping use and variations in genotyping methodology,
and to assess the effect of various genotyping methods on
estimates of treatment efficacy, a systematic review of the
use of genotyping in antimalarial clinical trials published
from 1995–2005 was performed. The primary goal was to
provide a comprehensive framework of prior work to help
develop a standardized approach to genotyping.
Methods
Search strategy
Two reviewers independently screened citations in the fol-
lowing electronic databases for relevant articles: Medline,
Embase, Cochrane CENTRAL Register of Controlled Tri-
als, BIOSIS, Web of Science, and Current Controlled Tri-
als. Search terms included "malaria", "falciparum",
"efficacy", "clinical trial", "drug", "therapy", and "treat-
ment". The search was limited to English language papers
published between 1995 and 2005. Reference lists from
primary and review articles were also searched. Individual
authors were contacted for unreported study characteris-
tics and additional data of interest. All published papers
were downloaded or copies of the original papers
obtained. Unpublished data were not sought.
Selection criteria
Published studies were included if they fulfilled all of the
following selection criteria: 1) treatment efficacy was a
reported outcome, 2) primary efficacy results were not
reported previously, and 3) human subjects with falci-
parum malaria were included. Studies restricted to com-
plicated or severe malaria, non-biomedical drugs (i.e.
herbal therapy), and prophylactic therapy were excluded.
Two independent reviewers judged study eligibility, and
disagreements were resolved by consensus.
Data abstraction
The two reviewers independently abstracted data from
included studies using a previously piloted data abstrac-
tion form. Disagreements were discussed and resolved by
consensus. Reviewers were not blinded to details of the
publications. The following information was abstracted
from all publications: 1) year of publication, 2) coun-
try(ies) where the study was done, 3) maximum duration
of patient follow-up, 4) treatment arms, 5) number of
patients enrolled in each treatment arm, and 6) whether
genotyping was performed to distinguish recrudescence
from new infections. For all studies that included geno-
typing, the following additional information was
abstracted: 1) earliest day following therapy on which
samples were collected for genotyping, 2) method used to
collect blood and extract DNA, 3) genotypic markers used,
4) method of distinguishing PCR products, 5) method
used to classify treatment outcomes based on genotyping
results, and 6) proportion of patients with various geno-
typing adjusted outcomes for each treatment arm. For two
studies, genotyping results were not published in the pri-
mary paper but were reported in subsequent publications.
These studies were included as having performed geno-
typing.
Data management and statistical analysis
All papers identified were entered into an EndNote
Library (Thomson ResearchSoft). Abstracted data were
double-entered into Microsoft Access and analysed using
Stata version 8 (Stata Corporation, College Station, TX.).
Count data were analysed using a Poisson regression
model. Categorical variables were compared using the
Chi-squared test. Univariate and multivariate analyses of
the association between various explanatory variables and
the proportion of genotyped recurrences classified as new
infections were done using logistic regression.
Results
All antimalarial trials
A total of 384 studies published between 1995 and 2005
were identified that included estimates of efficacy for the
treatment of uncomplicated falciparum malaria. Tempo-
ral trends in the number of published studies varied
according to the region of the world where they were per-
formed (Figure). In Africa, there was no significant change
in the number of studies published per year from 1995–
2000 (mean 15; p = 0.71), but the number increased
steadily from 15 in 2001 to 43 in 2005 (p < 0.0001). In
contrast, there has been no significant change in the
number of studies published annually from South and
East Asia (mean 11, p = 0.89) or the rest of the world com-
bined (mean 4.5, p = 0.16).
Antimalarial trials using genotyping
The main interest of this study was to investigate the use
of genotyping in antimalarial clinical trials. Considering
all studies included in this review from 1995–2005, 91
(24%) used genotyping to adjust estimates of treatment
efficacy, 269 (70%) did not use genotyping, and 24 (6%)
had no episodes of recurrent parasitaemia. Temporal and
geographic trends in the proportion of studies that used
genotyping were similar to trends in the number of stud-
ies as a whole (Figure 1). The first study to report the useMalaria Journal 2006, 5:122 http://www.malariajournal.com/content/5/1/122
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of genotyping to adjust estimates of treatment efficacy was
in 1997 from Africa. Between 1997 and 2002, the overall
proportion of studies from Africa that used genotyping
was 14% and did not change significantly over this time
period (p = 0.76). From 2003–2004 the proportion of
studies from Africa that used genotyping increased signif-
icantly to 33% (p = 0.008) and further increased to 58%
(p < 0.0001) in 2005. For studies conducted in South and
East Asia, genotyping was first reported in 1998 and was
used in 16% of studies published between 1998 and
1999. Since 2000, approximately 50% of studies from
south and east Asia have used genotyping, with no signif-
icant change in this proportion over time (p = 0.63). Con-
sidering studies done outside of Africa and south-east
Asia, none of 17 studies published prior to 2000 and only
three of 32 studies (9%) published since 2000 reported
using genotyping. The use of genotyping was also associ-
ated with studies that included ACTs and studies with
longer durations of follow-up. Considering studies pub-
lished after 1999, 45% of studies that included ACT regi-
mens used genotyping compared to less that 4% of studies
that did not include ACT (p < 0.0001). Similarly, 57% of
studies that followed patients 28 days or longer used gen-
otyping, compared to 23% of studies that followed
patients for less than 28 days (p < 0.0001).
Genotyping methods
The 91 trials which used genotyping were investigated to
determine methods and assess the effects of variations in
methods on the classification of outcomes. Genotyping
relies on the genetic diversity present in P. falciparum to
distinguish whether recurrent parasitaemia after therapy is
due to recrudescence of the initial parasite strain or to
infection with a new strain. To make this distinction,
blood samples are collected at baseline and then at the
time of recurrent parasitaemia, and parasite genotypes
from these two time points are compared. Because P. fal-
ciparum  is haploid in the human host and genotyping
markers are single-copy genes, each different allele
detected by a genotyping marker represents a genetically
distinct parasite strain. If the baseline and recurrent para-
sitaemia samples have matching alleles, recurrent parasi-
taemia is classified as recrudescence; if the two samples
have different alleles, recurrent parasitaemia is classified
as a new infection. The genotyping methods discussed
below have varied ability to measure the genetic diversity
of parasites. Greater ability to measure diversity increases
the sensitivity for detecting new infections, as it is less
likely that two different parasite strains will have a match-
ing allele by chance. Methods at all stages in the genotyp-
ing process, from when samples were collected to the
interpretation of results, varied widely between the 91 tri-
als that were assessed.
Sample collection and DNA extraction
Collection of baseline and recurrent parasitaemia samples
was evaluated first. All 91 trials collected blood samples
prior to antimalarial therapy to determine the P. falci-
parum alleles present at baseline, and two trials collected
additional samples on subsequent days (one or three days
after the onset of therapy) to broaden their definition of
the baseline alleles. Most trials only genotyped samples
from episodes of recurrent parasitaemia that occurred
after a defined number of days following therapy. Epi-
sodes before this defined cut-off were assumed to be due
to recrudescence. There was large variation in this cut-off
Annual number of trials with and without genotyping by  region Figure 1
Annual number of trials with and without genotyping 
by region. Total bar height represents all trials. White rep-
resents trials that used genotyping. Black represents trials 
that either did not use genotyping or did not have any epi-
sodes of recurrent parasitaemia to genotype.
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between trials, with trials evenly divided into three groups
– those with a cut-off less than one week (34%), at one
week (36%), or greater than one week (30%). The advan-
tage of a later cut-off is that fewer samples need to be gen-
otyped. However, if new infections occur before this cut-
off they are incorrectly classified as recrudescence, leading
to a falsely elevated drug failure rate. Of the nine trials
which genotyped within one week following the onset of
therapy and reported the day of their first new infection,
three (33%) had at least one new infection within the
week after therapy.
There was less variation in the type of sample collected
(Table 1). Most trials used spots of dried blood on filter
paper as the source of DNA, a method of collection which
requires a small amount of blood, obtainable from a fin-
ger prick, and which results in samples which are easy to
store and transport. DNA from samples was extracted pri-
marily using common laboratory reagents. Chelex extrac-
tion[6] was the most commonly reported DNA extraction
method, followed by standard phenol-chloroform extrac-
tion, with only 12% of studies reporting the use of more
expensive commercial purification kits. Chelex extraction
has the advantage of being inexpensive and quick and
easy to perform, and it does not require toxic reagents.
Genotyping markers
Once DNA was extracted, samples were genotyped using
methods which relied on size and sometimes sequence
variation of the genotyping markers. All markers reported
were genes of polymorphic surface antigens and were
amplified using the polymerase chain reaction (PCR),
though different primers and conditions were often
reported for the same marker. 98% of the trials for which
markers were reported used the highly variable merozoite
surface protein 2 (msp2) alone or in combination with
other markers (Table 1). The msp2 marker has the advan-
tage of greater genetic diversity than other commonly
used markers[7], which helps to increase sensitivity for
detecting new infections. Most trials used a combination
of two or more markers, with all combinations including
both  msp1  and  msp2, and with the most commonly
reported combination of msp1, msp2, and glutamine-rich
protein (glurp) used in over half of all trials. The advantage
of using a combination of markers for genotyping is that
it improves the ability to measure genetic diversity further,
as two parasite strains may have the same allele at one
marker but different alleles at another[8]. The most com-
mon method for amplifying msp1 and msp2 was nested
PCR, in which the second round of PCR used primers spe-
cific for distinct families of alleles for each marker. By
using family-specific primers, the ability to measure
Table 1: Characteristics of drug trials where genotyping was performed (n = 91)
Characteristic N (%)
Source of sample
filter paper 70 (77%)
whole blood/RBC pellet * 12 (13%)
not reported 9 (10%)
Method of DNA extraction
Chelex 38 (42%)
phenol/chloroform 17 (19%)
commercial kit 11 (12%)
methanol 1 (1%)
not reported 24 (26%)
Markers used
msp1 alone 2 (2%)
msp2 alone 20 (22%)
msp1 and msp2 19 (21%)
msp1, msp2 and glurp 46 (51%)
msp1, msp2 and others † 2 (2%)
not reported 2 (2%)
Interpretation of mixed results ‡
always a recrudescence 56 (62%)
always a new infection 17 (19%)
> half of RP alleles match baseline § 5 (5%)
not reported 13 (14%)
* One study used either filter paper or whole blood.
† One study used msp1, msp2 and csp. Another used msp1, msp2, glurp, trap, and pf60.1.
‡ A mixed result is defined here as a recurrent parasitaemia sample which shows both alleles that were present in the baseline sample as well as new 
alleles not seen at baseline.
§ RP = Recurrent parasitaemia sample. Four of five studies used msp2 alone and defined recrudescence as > half of RP alleles matching alleles found 
in the baseline sample. One study used msp1, msp2 and glurp and required a majority of RP alleles match baseline for every locus tested.Malaria Journal 2006, 5:122 http://www.malariajournal.com/content/5/1/122
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genetic diversity is increased, because alleles can be distin-
guished both by sequence variation between the families
as well as by the size of alleles within each family. In a
small proportion of trials, sequence variation in markers
was assessed after PCR amplification by using family-spe-
cific hybridization probes, restriction fragment length
polymorphism, direct sequencing, or a heteroduplex
tracking assay.
Once markers were amplified, different alleles were iden-
tified by separating PCR products by size using electro-
phoresis. Though a few trials used polyacrylamide gel
electrophoresis, the vast majority of trials relied on agar-
ose, which provides lower resolution than polyacryla-
mide, decreasing the ability to detect genetic differences,
but is faster, less expensive, and easier to perform. Many
of the trials which used agarose gel electrophoresis did not
specify whether comparisons between baseline and recur-
rent parasitaemia samples were made based on visual
inspection or by comparing the measured size of alleles.
Only 15% of trials specifically mentioned using a compu-
ter programme to size alleles. Of the trials which men-
tioned sizing alleles, the criteria used to determine
whether alleles from two different samples were the same
or different varied and were often not reported.
Interpretation of results
Genotyping patterns are easy to compare when only one
parasite strain, and thus one allele per marker, is present
in baseline and recurrent parasitaemia samples. However,
in high transmission areas such as Africa, where the
majority of trials using genotyping are now performed,
multiple parasite strains are often present. All trials con-
sidered an outcome recrudescence if all alleles from both
samples matched and new infection if no alleles matched.
However, trials varied in how they interpreted a mixed
result, in which some but not all of the alleles present in
the recurrent parasitaemia sample were present at base-
line. 62% of trials classified mixed results as recrudes-
cence, since at least one parasite strain may have survived
therapy (Table 1). This is the more conservative defini-
tion, erring on the side of detecting recrudescence, and has
been recommended for use in drug efficacy trials[8]. How-
ever, in high transmission areas when multiple alleles are
present, the probability of at least one match occurring
between two samples by chance may be very high, even at
multiple markers, and using this conservative definition
may significantly overestimate the rate of drug failure[7].
Of the trials that classified mixed results as recrudescence,
43% referenced the same paper for their methods[9]. This
paper included the criterion that for an outcome to be
considered recrudescence the probability of alleles from
the baseline and recurrent parasitaemia samples matching
by chance be less than 0.05, though it is unclear how
many trials referencing this paper actually estimated this
probability.
Impact of genotyping methods on drug efficacy measures
Among the 91 antimalarial trails which used genotyping,
the majority of the 175 treatment arms used either an ACT
or a non-artemisinin monotherapy (Table 2). The per-
centage of treatment outcomes requiring genotyping
would be expected to be higher for trials conducted in
higher transmission areas, since new infections would be
more common, and also higher with less efficacious
drugs, since recrudescent infections would be more com-
mon. In Africa, where transmission intensity is high, the
median percentage of subjects per arm requiring genotyp-
ing was twice as high (25%) as for trials outside of Africa
(12.5%). Of the 46 trials requiring genotyping of at least
50 samples, 40 were conducted in Africa. Looking at drug
class, the median percentage of subjects per arm requiring
genotyping was highest for non-artemisinin monothera-
pies (31%) and lowest for ACTs (17%). The success of
genotyping varied widely, and more than one third of
arms were not successful in genotyping at least 91% of
subjects for which genotyping was required (Table 2).
Reasons for unsuccessful genotyping included unsuccess-
ful amplification of parasite DNA, inability to interpret
PCR results, loss of samples, and the decision to only gen-
otype a subset of samples.
The outcome measure for determining the effects of trial
location and genotyping methods on results was the per-
cent of successfully genotyped recurrences classified as
new infections (Table 2). Univariate and multivariate
logistic regression analyses were performed to assess the
roles of five separate factors on the percent of successfully
genotyped results classified as new infections: the number
of markers, the interpretation of mixed results, the type of
antimalarial drug studied, the geographic region in which
the study took place, and the duration of follow-up. Treat-
ment arms were classified into two outcome groups: less
than 50% or at least 50% of successfully genotyped recur-
rences classified as new infections. Excluding eight arms
with no recurrences, 11 arms without data on the number
of patients who required genotyping, and 1 arm for which
no recurrence was successfully genotyped, 78 arms fell
into the first outcome group, and 77 fell into the second.
An additional 16 treatment arms were excluded because
data were not available on the number of genotyping
markers used or the interpretation of mixed results, leav-
ing 139 treatment arms included in the final analysis.
Univariate logistic regression analysis showed that both
the use of combination therapy (either ACT or non-ACT)
and follow-up of greater than 28 days significantly
increased the odds of classifying at least 50% of success-
fully genotyped recurrences as new infections (Table 3).Malaria Journal 2006, 5:122 http://www.malariajournal.com/content/5/1/122
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Combination therapy is generally more effective than
monotherapy, and therefore would be expected to have
fewer recrudescent infections, leading to a larger propor-
tion of recurrent parasitaemia due to new infections. With
longer follow up, there is more time for a new infection to
occur, also increasing the proportion of recurrent parasi-
taemia due to new infections. When multivariate logistic
regression analysis was used to account for confounding
between variables, an interpretation of mixed results as
not always a recrudescence and the location of the study
arm in Africa were also found to significantly increase the
odds of classifying at least 50% of successfully genotyped
recurrences as new infections. The interpretation of mixed
results as a new infection will result in more outcomes
classified as new infections, though possibly missing true
drug failures as discussed previously. The higher transmis-
sion in Africa compared with the rest of the world also
makes new infection during follow-up more likely. The
use of at least three genotyping markers was not found to
increase the odds of classification as new infection in
either univariate or multivariate analysis.
Discussion
The results of this study show that the use of genotyping
for clinical antimalarial efficacy trials increased dramati-
cally from 2001–2005, especially in Africa where the
majority of these trials are now performed. There was
wide variation in the methods used for all steps in the gen-
otyping process, from the choice of subjects to genotype
to the interpretation of mixed results. Trials in Africa had
the highest proportion of subjects with recurrent parasi-
taemia, and thus the largest proportion of outcomes
potentially affected by genotyping. Several factors had a
significant effect on genotyping outcomes in the multivar-
iate logistic regression analysis. The interpretation of
mixed genotyping results as not always a recrudescence,
the use of ACT, the location of a trial in Africa, and a fol-
low-up duration of more than 28 days were all associated
with a statistically significant increase in the number of
recurrent parasitaemia episodes classified as new infec-
tions.
These data demonstrate that genotyping-corrected esti-
mates of antimalarial efficacy from clinical trials can vary
due to the setting in which genotyping is applied and the
genotyping methods used. Variations in efficacy estimates
may not have a major effect on treatment policy when
drug failure rates are very high. However, with the intro-
duction of more efficacious therapies such as ACT and the
recent WHO recommendation that a therapy be aban-
doned if failure rates are greater than 10%[3], variations
in efficacy estimates attributable to genotyping methods
Table 2: Characteristics of individual treatment arms where genotyping was performed (n = 175).
Characteristic n (%)
Drug regimen
non-artemisinin monotherapy 68 (39%)
non-artemisinin combination therapy 29 (17%)
artemisinin monotherapy 6 (3%)
artemisinin combination therapy 72 (41%)
Total number of patients requiring genotyping *
1–9 42 (24%)
10–19 30 (17%)
20–49 54 (31%)
≥50 30 (17%)
no samples to genotype 8 (5%)
data not available 11 (6%)
Percent of samples successfully genotyped †
≤50% 14 (9%)
51% – 90% 46 (29%)
91% – 99% 25 (16%)
100% 71 (46%)
Percent of successfully genotyped samples classified as new infections
0% 20 (13%)
1% – 24% 25 (16%)
25% – 49% 33 (21%)
50% – 74% 41 (26%)
75% – 99% 24 (15%)
100% 12 (8%)
* Total number of patients who experienced recurrent malaria/parasitaemia excluding those patients whose recurrence occurred prior to the 
earliest day following therapy on which samples were collected for genotyping.
† Samples not successfully genotyped include those for which genotyping was not attempted, for which genotyping failed to give a result, or for 
which genotyping gave indeterminate results.Malaria Journal 2006, 5:122 http://www.malariajournal.com/content/5/1/122
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may affect policy decisions. A possible example of varia-
tion due to the setting in which genotyping was applied is
seen when comparing results from four recent antimalar-
ial trials of the ACT dihydroartemisinin plus piperaquine
(DHA-PQP). This ACT has only recently become availa-
ble, and there is little reason to suspect preexisting drug
resistance to either component outside of China. Accord-
ingly, three trials performed in South East Asia, where P.
falciparum  transmission is relatively low, demonstrated
failure rates of 0–0.6% for this combination at 42 or 63
days [10-12]. In contrast, another study performed in
Rwanda, where P. falciparum transmission is higher,
showed higher rates of drug failure at 28 days: 1.1%,
1.3%, and 11.4% at each of three sites[13]. Rukara, the
site with the highest rates of drug failure in this and a pre-
vious study[14] also had a much higher rate of new infec-
tion than the other two sites. Thus, while it is possible that
the higher DHA-PQP failure rate in Rukara was due to a
higher level of aminoquinoline resistance[13], another
possibility is that higher transmission in Rukara led to a
greater number of new infections which were misclassi-
fied as recrudescent. It is important to recognize the pos-
sibility that the accuracy of genotyping methods may vary
across different settings, and this variation must be con-
sidered when comparing study results.
The WHO has made great strides in standardizing antima-
larial clinical trial protocols, resulting in relatively uni-
form classification of treatment outcomes and aiding in
the comparison of drug efficacy results between trials. The
use of genotyping is now recommended for all trials[3],
but both the lack of standardization of genotyping meth-
ods and the lack of criteria for appropriate methods in dif-
ferent geographic settings can lead to difficulty in
comparing efficacy results. Variations in some aspects of
genotyping, such as collection of blood on filter paper ver-
sus whole blood, are unlikely to affect outcomes. How-
ever, different interpretations of mixed results, as has been
shown here and previously[5] may have a large effect on
efficacy outcomes. Some studies have in the past chosen
to define mixed results in recurrent parasitaemia samples
as new infections in high transmission areas, as the lim-
ited resolution of genotyping methods otherwise led to
too many genotyping outcomes falsely misclassified as
recrudescence[7]. Ideally, however, higher resolution
methods should be used so that the recurrence of even
one allele can be classified as drug failure[8]. One way to
improve resolution is to increase the number of genotyp-
ing markers used. In this analysis, the effect of the number
of genotyping markers used was not statistically signifi-
cant, possibly due to a lack of statistical power, other con-
founders not being assessed in the multivariate analysis,
or the fact that more than three markers or markers with
greater diversity are needed before better discrimination is
achieved. A recent review of genotyping in two laborato-
ries, however, showed that adding a second genotyping
marker resulted in 15.5% and 18% of recrudescent infec-
tions being reclassified as new infections[15]. Greater dis-
criminatory capacity of genotyping methods, possibly
afforded by the addition of new markers such as microsat-
ellites, may improve the ability to detect new infections in
high transmission areas such as much of Africa, and
should be further evaluated[16].
Conclusion
Standard criteria for genotyping methods, including
which methods provide enough discriminatory capacity
for different levels of transmission and what level of gen-
otyping misclassification is acceptable, should be decided
in order to estimate drug resistance rates for P. falciparum
more accurately and compare results between trials more
easily. The need for the evaluation and standardization of
Table 3: Effect of methods on the percent of outcomes classified as new infections (n = 139).
Explanatory Variable Univariate Analysis Multivariate Analysis
OR* (95% CI) p-value OR* (95% CI) p-value
Number of markers
≥3 markers vs. 1–2 markers 1· 09 (0.56–2· 13) 0.80 1· 28 (0.45–3· 65) 0.64
Classification of mixed results†
not always recrudescence vs. always recrudescence 1· 92 (0.91–4· 03) 0.09 3· 31 (1· 22–9· 01) 0.02
Treatment group
artemisinin combination therapy vs. monotherapy 8· 20 (3· 52–19· 11) < 0.0001 8· 56 (3· 34–21· 94) < 0.0001
non-artemisinin combination therapy vs. monotherapy 2· 72 (1· 03–7· 16) 0.04 2· 30 (0.82–6· 47) 0.12
Geographic region
Africa vs. rest of the world 0.87 (0.44–1· 71) 0.68 3· 30 (1· 01–10.84) 0.05
Maximum duration of follow-up
> 28 days vs. ≤ 28 days 2· 54 (1· 23–5· 24) 0.01 4.10 (1· 28–13· 15) 0.02
* Odds Ratio for the outcome defined as: ≥ 50% of samples successfully genotyped were classified as new infections
† Mixed results defined as a sample from the day of recurrent parasitaemia containing both alleles present in the baseline sample and new alleles not 
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genotyping methods is greatest in Africa, where the most
antimalarial trials are performed, the highest percentage
of outcomes need genotyping, and the interpretation of
genotyping is the most difficult. The creation of one or
more genotyping reference laboratories in Africa may help
to establish these standards and aid in the surveillance for
drug resistance and identification of the most appropriate
antimalarial therapies.
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